Synonyms: ILV-094
Compound class:
Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab [1]. |
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
9137 | fezakinumab |
Synonyms |
ILV-094 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 323 |
Other databases | |
GtoPdb PubChem SID | 318164800 |
Search PubMed clinical trials | fezakinumab |
Search PubMed titles | fezakinumab |
Search PubMed titles/abstracts | fezakinumab |